Who invested in Aquinox Pharmaceuticals?
Aquinox Pharmaceuticals's investors include Johnson & Johnson Development Corporation (JJDC), Ventures West, Pfizer, Baker Brothers Investments and BC Advantage Funds, and 2 more on record.
Canada · Series C startup
7 rounds we have observed, with the 7 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$74Mraised across 7 rounds since 2007, from 7 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
Reported by finance.yahoo.comSEC filing: $26 sold, first sale Mar 2013
No investor was named in the report.
Reported by sec.govSEC filing: $3.5M sold, first sale Sept 2011
No investor was named in the report.
Reported by sec.govSEC filing: $9 sold, first sale Jan 2011
No investor was named in the report.
From a historical funding recordSEC filing: $3.5M sold, first sale Jun 2010
Reported by aqxpharma.comSEC filing: $3.5M sold, first sale Jun 2010
No investor was named in the report.
Reported by sec.govSEC filing: $4.8M sold, first sale Mar 2010
From a historical funding record
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Aquinox Pharmaceuticals's investors include Johnson & Johnson Development Corporation (JJDC), Ventures West, Pfizer, Baker Brothers Investments and BC Advantage Funds, and 2 more on record.
Aquinox Pharmaceuticals has raised $74M across 7 rounds since 2007.
Aquinox Pharmaceuticals's most recent round was a Series C of $18M in Apr 2013.
Aquinox Pharmaceuticals's largest round on record is $25M (Series B), in Jun 2010.
Aquinox Pharmaceuticals's first round on record, in Jun 2007, was backed by Johnson & Johnson Development Corporation (JJDC), Ventures West and BC Advantage Funds and 1 others.
Aquinox Pharmaceuticals's latest named round is a Series C, in Apr 2013.
Aquinox Pharmaceuticals is based in Canada.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.